Overview

Anti PD-1 Neo-adjuvant Treatment for NSCLC

Status:
Recruiting

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

A single arm, phase I, dose escalation trial and expansion cohort, examining the safety and feasibility of neoadjuvant pembrolizumab treatment for early resectable NSCLC patients. Hypothesis: The investigators hypothesize that response rate to neo-adjuvant pembrolizumab will be higher than the response rate of advanced NSCLC patients.

Phase:

Phase 1

Details

Lead Sponsor:

Jair Bar, M.D., Ph.D.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab